Garuda - Garba Rujukan Digital

Article Per Year (5 Year)

All

Indonesian Journal of Cancer

ijoc
Website

Published by National Cancer Center-Dharmais Cancer Hospital

ISSN : 19783744 EISSN : 23556811 DOI : https://www.doi.org/ 10.33371

Core Subject : Health, Science,

Biochemistry, Genetics & Molecular Biology Immunology & microbiology Medicine & Pharmacology Public Health

Indonesian Journal of Cancer is a peer-reviewed and open-access journal. This journal is published quarterly (in March, June, September, and December) by Dharmais Cancer Hospital - National Cancer Center. Submissions are reviewed under a broad scope of topics relevant to experimental and clinical cancer research. Articles are original research that needs to be disseminated and written in English. All submitted manuscripts will go through the double-blind peer review and editorial review before being granted acceptance for publication. The journal publishes original research articles, case reports, and review articles under the following categories: cancer management, cancer prevention, cancer etiology, epidemiology, molecular oncology, cancer diagnosis and therapy, tumor pathology, surgical oncology, medical oncology, radiation oncology, interventional radiology, as well as early detection.

Arjuna Subject : Kedokteran - Onkologi

Articles 562 Documents

13 14 15 16 17

Hubungan antara Pemakaian KB Hormonal dengan Kejadian Kanker Payudara di Poli Onkologi Satu Atap RSUD Dr. Soetomo, FebruariApril 2015 DITYA AYU INTAN SETIOWATI; EDDY HERMAN TANGGO; ROOSTANTIA INDRAWATI SOEBIJANTO
Indonesian Journal of Cancer Vol 10, No 1 (2016): Jan - Mar 2016
Publisher : National Cancer Center - Dharmais Cancer Hospital

ABSTRACTThe aim of this study is to search relationship between using of hormonal contraception and breast cancer incidence. This study uses observational analytic method with case contol design. Group case is the women in POSA RSUD Dr. Soetomo diagnosed as breast cancer patient. Group control is the women in POSA RSUD Dr. Soetomo who are not diagnosed breast cancer. Then, calculate the Odds Ratio using 2x2 crosstabulation and p value using chi square statistictest with SPSS program. There are 96 women of case group sample and 96 women of control group sample are used in this study. Calculation of regression logistic multivariate analysis shows that there is significant relationship between using hormonal contraception and breast cancer incidence in POSA RSUD Dr. Soetomo with p=0.001, OR=2.990, woman who uses hormonal contraception has 2.990 times risk bigger than the woman who doesnt use hormonal contraception. There is significant relationship between using hormonal contraception and breast cancer incidence inPOSA RSUD Dr. Soetomo and woman who uses hormonal contraception has 2,304 times risk bigger than the woman who doesnt.ABSTRAKTujuan dari penelitian ini adalah untuk mengetahui hubungan antara pemakaian KB hormonal dengan kejadian kanker payudara. Penelitian ini menggunakan metode analisis dengan desain kasus kontrol. Kelompok kasus adalah wanita di POSA RSUD Dr. Soetomo yang menderita kanker payudara, dan kelompok kontrol adalah wanita di POSA RSUD Dr. Soetomo yang tidak menderita kanker payudara. Kemudian Rasio Odds dihitung menggunakan tabel 2x2 dan nilai p menggunakan tes chi square dengan program SPSS. Ada 96 kelompok kasus dan 96 kelompok kontrol yang ada dalampenelitian ini. Setelah dihitung dengan analisis multivariat regresi logistik menunjukkan bahwa ada hubungan bermakna antara penggunaan KB hormonal dengan kejadian kanker payudara pada wanita di POSA RSUD Dr. Soetomo dengan nilai p= 0,001 dan OR=2,990 yang berarti wanita yang menggunakan KB hormonal memiliki risiko 2,990 kali lebih besar terkena kanker payudara dibanding yang tidak menggunakan. Kesimpulannya, ada hubungan bermakna antara pemakaian KB hormonal dengan kejadian kanker payudara pada wanita di POSA RSUD Dr. Soetomo dan wanita yang menggunakan KB hormonal memiliki risiko 2,990 kali lebih besar terkena kanker payudara dibanding yang tidak menggunakan.

Loss of Phosphatase and Tensin Homologue (PTEN) Expression Associated with Higher Risk Grade Group Gleason Prostate Adenocarcinoma in Sanglah Hospital Denpasar Tjandra Kristiana; I Gusti Ayu Sri Mahendra Dewi; Luh Putu Iin Indrayani Maker; Herman Saputra; Ni Putu Sriwidyani; I Made Muliarta
Indonesian Journal of Cancer Vol 13, No 4 (2019): December
Publisher : National Cancer Center - Dharmais Cancer Hospital

Background: Prostate cancer is the second most common malignancy in men and the fifth most common cause of death worldwide. In Asia, 59.3% of patients come for the advanced stage treatment. PTEN inactivation is identified in about 20% of primary prostate tumors in radical prostatectomy and the loss of PTEN is associated with poor clinical and pathological outcomes. The purpose of this study is to prove that there is an association between PTEN expression and risk grade group Gleason prostate adenocarcinoma in Sanglah Public Hospital, Denpasar.Methods: This is a cross-sectional study. The sample size of this study was 35 paraffin blocks. These samples were selected by proportional stratified random sampling from hematoxylin-eosin preparation. Prostate adenocarcinoma was regrouped into 3 categories based on NCCN risk stratification: low risk grade group Gleason (Gleason score ≤ 6), intermediate risk grade group Gleason (Gleason score 7), and high-risk grade group Gleason (Gleason score 8–10). Immunohistochemistry examination of PTEN was performed and the expression was evaluated by scoring method. The data were analyzed by Chi-square and logistic regression.Results: The analysis result showed that there is an association between PTEN expression and risk grade group Gleason that is statistically significant. The loss of PTEN expression associated with higher risk grade group Gleason is of the higher proportion with p=0.001; PR 3.339; 95% CI: 1.296–8.599, but there is no association between the proportion loss of PTEN expression heterogeneously or homogeneously and the risk grade group Gleason with p=0.742; PR 0.663; 95% CI: 0.179–2.457.Conclusions: This study has proved that PTEN expression is associated with higher risk grade group Gleason prostate adenocarcinoma.

Palliative Care: an Interdisciplinary Approach for Patients with Life Threatening Illness Maria Astheria Witjaksono
Indonesian Journal of Cancer Vol 1, No 1 (2007): Jan - Mar 2007
Publisher : National Cancer Center - Dharmais Cancer Hospital

Patients with life threatening illness area characterized by multi-aspect of suffering. These various aspects of suffering area interrelated require a total comprehensive care by an interdisciplinary team. Palliative care means to address the total suffering of the patients and to maintain a rational hope when cure is absurd. Palliative care emphasizes the essential role of the family. Although the awareness about palliative care has been increasing, its development in Indonesia is still left behind compared to that of other Asian Countries. This paper discusses the definition of palliative care, total suffering, interdisciplinary approach, integration of palliative care in cancer management & barriers to Palliative Care.

Re-Irradiation of Recurrent Nasopharyngeal Cancer: A 4-year Follow-up Study of Treatment using 3-Dimensional Conformal Radiotherapy Samuel Kelvin Ruslim; Selviant Selviant; Aviciena bin Iskandar; Sielvyana Sie; Agustinus Darmadi Hariyanto; Monika Kencana Dewi
Indonesian Journal of Cancer Vol 16, No 1 (2022): March
Publisher : National Cancer Center - Dharmais Cancer Hospital

Introduction: Nasopharyngeal cancer (NPC) is a prevalent diagnosis of head and neck cancers (HNC) in Asia. In Indonesia, it is estimated that there are 12,000 new cases per year. Case Presentation: The author reports a 25-year-old male patient with recurrent NPC. This patient was first diagnosed with NPC stage IVB in 2013 and was treated by chemoradiation. In 2016, he found another mass in his neck. The biopsy result showed the recurrence of the NPC with histopathology of Undifferentiated carcinoma (WHO type III). Re-irradiation was planned, and the patient subsequently received 3D-Conformal Radiotherapy (3D-CRT) at our department. Four years after the completion of re-irradiation, the patient was alive and well with no signs of recurrence but still complained about late toxicities like trismus and fibrotic neck. Conclusions: In this study, we discuss the use of 3D-CRT in the re-irradiation of NPC with its limitation on obtaining optimum dose sculpture compared to more sophisticated and widely spread modalities like intensity-modulated radiotherapy (IMRT). However, with careful planning, we can still obtain optimum tumor dose, minimize organs at-risk (OAR) dose, and subsequently late toxicities that come after. We hope that this study can bring hope to centers with limited facilities, and we suggest further studies on re-irradiation, especially in OAR dose tolerance guidelines.

Diagnosis Kanker Prostat dalam Perspektif Spesialis Urologi di Indonesia: Sebuah Survei Kuesioner RICHARD MONOARFA; AGUS HAMID; CHAIDIR MOCHTAR; RAINY UMBAS
Indonesian Journal of Cancer Vol 6, No 3 (2012): Jul - Sep 2012
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v6i3.201

Tujuan: untuk mengetahui upaya diagnosis kanker prostat yang dilakukan oleh spesialis urologi di Indonesia. Metode: Dilakukan pembagian kuesioner yang dirancang sendiri kepada Spesialis Urologi di Indonesia. Kuesioner berisi 11 pertanyaan tentang jenis dan indikasi pemeriksaan yang dilakukan, serta fasilitas yang tersedia di tempat responden dalam penegakan diagnosis kanker prostat.Hasil: Sebanyak 65 (36%) dari 182 (saat penelitian ini dilakukan) spesialis urologi di Indonesia mengembalikan formulir kuesioner. Dari jenis RS primer tempat bekerja terbanyak berasal dari RS swasta (35%), disusul RS pendidikan utama Fakultas Kedokteran (32%). Seluruh responden menjadikan lower urinary tract symptoms (LUTS) sebagai indikasi untuk melakukan pemeriksaan colok dubur. Selain itu, 83% responden juga menjawab bahwa peningkatan PSA sebagai salah satu indikasi pemeriksaan colok dubur. Pemeriksaan PSA dilakukan oleh 72% responden terhadap penderita dengan kecurigaan kanker prostat tanpa melihat usia. Sebanyak 66% responden mengerjakan sendiri pemeriksaan transrektal ultrasonografi (TRUS) dan biopsi, 18% merujuk pada sejawat lain di provinsi yang sama, dan 15% tidak memiliki fasilitas TRUS dan biopsi di provinsi tempat bekerja. Sebanyak 75% responden memiliki fasilitas bone scan di Rumah Sakit primer, atau tersedia di RS pada provinsi yang sama. Indikasi tersering melakukan biopsi prostat adalah pada PSA lebih dari 10 ng/ml tanpa melihat usia. Sebanyak 86% responden melakukan biopsi pada kecurigaan kanker prostat melalui colok dubur tanpa melihat usia. Sembilan puluh persen responden menggunakan antibiotik profilaksis golongan Kuinolon untuk biopsi prostat. Sebanyak 46% menggunakan analgesia oral atau suppositoria atau kombinasi keduanya sebagai analgesia dalam biopsi prostat.Kesimpulan: Dalam mendiagnosis kanker prostat, spesialis urologi di Indonesia melakukan pemeriksaan colok dubur, PSA, dan TRUS biopsi prostat. Namun, masih terdapat perbedaan pendapat tentang indikasi dan waktu dilakukannya masing-masing pemeriksaan. Ketersediaan fasilitas diagnostik juga berpengaruh terhadap diagnostik kanker prostat di Indonesia. Belum tersedianya guideline Nasional pada saat penelitian ini dilakukan, diduga menyebabkan perbedaan pendapat tersebut.Kata kunci: biopsi, diagnosis, kanker prostat, spesialis urologi, TRUS

Simple Bone Cyst Management: Percutaneous Steroid Injection Versus Curettage With Hydroxiapatite ACHMAD FAUZI KAMAL; RIZA APRIZAL; YOGI PRABOWO
Indonesian Journal of Cancer Vol 11, No 2 (2017): April - June
Publisher : National Cancer Center - Dharmais Cancer Hospital

ABSTRACT The main goals of the therapy of simple bone cyst (SBC) are to get the bone healing, prevent pathological fractures, and management of pain symptom. There are various methods of the SBC treatments, however they still remain controversial because of their healing rate and invasiveness of surgery. A total of 10 SBC patients were divided into two groups namely curretage with hydroxyapatite (HA) and decompression and percutaneous steroid injection (PSI). PSI was performed three times at intervals of each month. The mean followup of 12-26 months. Evaluation of functional outcome by Musculoskeletal Tumour Society (MSTS) score and supported with radiologically based on Chang criteria. There were 5 patients (proximal femur 2; proximal humerus 2, radius 1) performed curretage with HA therapy. Remaining 5 patients (proximal femur 3; proximal humerus 1; calcaneus 1) were performed PSI therapy. PSI group had better MSTS score, particulary at month 3 (55%) and month 6 (84%) than curettage with HA therapy (47% and 69.3%). Complete bone healing was found in both group at month 12 follow up, however solid union occurred faster in PSI group. PSI tends to have faster and better functional outcome than curettage and HA. Curettage with HA and PSI have similar complete bone healing at month 12 follow up. ABSTRAKTarget utama penalaksanaan simple bone cyst (SBC) adalah mencapat penyembuhan tulang yang sempurna, mencegah fraktur patologis dan mengatasi gejala nyeri. Ada beberapa metode penatalaksanaan SBC, namun demikian masih menjadi perdebatan dikarenakan perbedaan angka penyembuhannya dan jenis pembedahan yang invsif. Sepuluh pasien yang didiagnosis SBC dikelompokkan menjadi kelompok yang mendapat tindakan curretage dan pengisian defek dengan hydroxyapatite (HA) dan kelompok dekompresi dan percutaneous steroid injection (PSI). Prosedur PSIdilakukan sebanyak 3x dengan interval waktu satu bulan. Follow up dilakukan selama 12 – 26 bulan. Evaluasi luaran fungsional menggunakan Musculoskeletal Tumour Society (MSTS) score dan secara radiologi sesuai criteria Chang. Terdapat 5 pasien (2 femur proksimal, 2 humerus proksimal, dan 1 radius) yang dilakukan prosedur curretage dan pengisian defek dengan HA. Lima pasien sisanya ( 3 fenur proximal, 1 humerus proximal dan 1 calcaneus) dilakukan prosedur PSI. Luaran fungsional Kelompok PSI memiliki MSTS score yang lebih baik, khususnya pada bulan ke- 3 (55%) dan bulan ke-6 (84%) daripada kelompok curettage dengan HA (47% dan 69.3%). Penyembulan tulang sempurna menunjukkan hasil yang sama pada evaluasi bulan ke-12, tetapi solid union didapatkan lebih cepat pada kelompok PSI. Kelompok PSI memiliki kecenderungan solid union dan luaran fungsional yang lebih cepat daripada kelompok curettage dengan HA. Kedua kelompok mencapai penyembuhan sempurna pada bulan ke-12 follow up

Real-World Experience of Telbivudine and Lamivudine as Antiviral Prophylaxis for Chemotherapy-Related Hepatitis B Reactivation Lianda Siregar; Imelda Maria Loho; Agus Sudiro Waspodo; Siti Nadliroh; Rahmanandhika Swadari; Rizka Andalusia; Leovinna Widjaja
Indonesian Journal of Cancer Vol 15, No 1 (2021): March
Publisher : National Cancer Center - Dharmais Cancer Hospital

Background: There is currently no data regarding the efficacy of prophylactic telbivudine in hepatitis B patients undergoing chemotherapy. This study aims to describe the results of preemptive telbivudine and lamivudine to prevent chemotherapy-related HBV reactivation.Methods: The medical records of all patients with HBsAg positive or HBs-Ag negative, anti-HBc positive, who were referred to the hepatology clinic between May 2014 and December 2016, were retrospectively reviewed. As this is a descriptive study, no statistical analysis was done.Results: A total of 52 patients with prophylactic telbivudine or lamivudine therapy were included, with 26 patients in each group. Rituximab-based treatment was given in nine and five patients in the telbivudine and lamivudine group, respectively. The number of patients who completed antiviral treatment up to six months after chemotherapy was 17 patients in each group. There was less incidence of HBV reactivation in the telbivudine group (2 of 17 patients, 11.8%) than in the lamivudine group (7 of 17 patients, 41.2%). Delayed reactivation was noticed in 1 of 2 patients in the telbivudine group and 3 of 7 patients in the lamivudine group. The median log10[HBV DNA] at reactivation was 4.52 (1.70 – 8.35) IU/mL. Severe hepatitis was observed in two patients in the lamivudine group and one patient in the telbivudine group. Of 34 patients who completed antiviral treatment, two patients died due to primary cancer. No interruption of chemotherapy or mortality due to hepatitis was noticed in both groups.Conclusions: Preemptive telbivudine or lamivudine in HBsAg positive or HBsAg negative, anti-HBc positive patients seems to be a good treatment option.

Akurasi Kadar Lysophosphatidic Acid Plasma dan Ca125 Serum Penderita Tumor Ovarium Jenis Epitel untuk Prediktor Keganasan Ovarium TRI APRILIAWAN; BRAHMANA ASKANDAR
Indonesian Journal of Cancer Vol 8, No 2 (2014): April-Juni 2014
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v8i2.300

This study was conducted to determine and compare the sensitivity, specificity, positive predictive value and negative predictive value between CA125, Lysophosphatidic Acid Plasma (LPA) and combination of LPA - CA125 in patients with ovarian mass.This study was a analytic observational cross sectional studies, with 56 subjects who had ovarian tumors, who had the inclusion and exclusion criteria research, in Department of Obstetrics and Gynecology FK-Unair/dr. Soetomo Hospital, Surabaya. After that, patients performed surgery, and histopatology examination of operation specimens in this hospital. Inclusion criteria for this study were patients with epithelial ovarian tumors from Anatomical Pathology examination. The 56 study subjects , we were divided into 2 groups based on histopatological examination, one group with 31 subjects we classified into epithelial type malignant ovarian tumors study group, while the other group consist of 25 subjects we classified into epithelial type benign ovarian tumors study group.Sensitivity, specificity, positive predictive value, negative predictive value of CA125 was 87.1%; 28%; 60%; and 63.8%. Sensitivity, specificity, positive predictive value, negative predictive value LPA was 51.6%; 76%; 72.7%; and 55,9%. And sensitivity, specificity, positive predictive value, negative predictive value combination LPA - CA125 was 45.2%; 92%; 87.5%; and 57.5%. And in this study we get the CA125 cut-off at 50 u/mL gives better results than 35 u/mL, whereas the LPA cut-off 2.5 ?M still the best, although the Kappa analysis results for both are not significant.In this study, plasma LPA level patients with ovarian tumor can not be used as a tumor marker for epithelial malignant ovarian cancer. CA125 levels can be used as a tumor marker for epithelial malignant ovarian cancer, while combination of CA125 levels and LPA levels increase the specificity but does not increase the sensitivity. This was contrast with previous studies that the sensitivity and specificity of plasma LPA is excellent and they proposed use LPA plasma as a tumor marker.

Penanganan Kanker Prostat Stadium II pada Penderita Berusia 70 Tahun atau Lebih: Pengalaman Dua Rumah Sakit Tersier di Jakarta Rainy Umbas
Indonesian Journal of Cancer Vol 3, No 4 (2009): Oct - Dec 2009
Publisher : National Cancer Center - Dharmais Cancer Hospital

Saat ini, terdapat beberapa cara pengobatan kanker prostat dan usia penderita merupakan salah satu faktor untuk menentukan pilihan pengobatan selain derajat dan stadium penyakit. Tujuan penelitian ini adalah untuk mengetahui cara dan hasil pengobatan penderita kanker prostat stadium II yang berusia 70 tahun atau lebih di rumah sakit Cipto Mangunkusumo dan rumah sakit kanker Dharmais, Jakarta. Selama periode Januari 1995 sampai dengan Desember 2007, terdapat 74 penderita kanker prostat sesuai tujuan penelitian ini di kedua rumah sakit tersebut. Terdapat 40,5% penderita yang mendapat radioterapi dengan rerata survival 54,3 bulan dan 47,3% menerima pengobatan hormonal dengan rerata survival 55,2 bulan. Sekitar 60% pengobatan hormonal dilakukan dengan pemberian suntikan GnRH agonis. Angka survival 5 tahun penderita yang mendapat radioterapi lebih besar dibanding penderita yang mendapat pengobatan hormonal, yaitu masing-masing 69,3% dan 63,6% namun secara statistik tidak berbeda bermakna. Sebagai kesimpulan, penderita kanker prostat stadium II berusia lanjut lebih banyak yang mendapat pengobatan hormonal. Angka survival 5 tahun pada penderita yang mendapat radioterapi lebih baik daripada penderita yang diobati dengan cara lain walaupun tidak berbeda bermakna.Kata kunci: radioterapi, prostatektomi radikal, terapi hormonal, pengobatan berlebihan, pengobatan yang kurang.

Karsinoma Pelvis Renis dan Ureter di Jakarta: Karakteristik dan Faktor Risiko YEVRI ZULFIKAR; RAINY UMBAS; CHAIDIR A MOCHTAR
Indonesian Journal of Cancer Vol 4, No 2 (2010): Apr - Jun 2010
Publisher : National Cancer Center - Dharmais Cancer Hospital

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.33371/ijoc.v4i2.89

To study the characteristics,diagnosis and role of upper urinary tract stone as risk factors of renal pelvis and ureter malignancy. Data were collected from medical record of Urology Clinic Ciptomangunkusumo Hospital and Dharmais Cancer Hospital, Jakarta during the period between January 1995 and December 2009. The clinical factors which were studied are age, gender, symptoms, history of stone disease, imaging, histopathology , primary lesions of the tumor, and stage. There were 42 renal pelvis and ureter carcinoma patients during 15 years period. With mean age of 53.5 years (range 33 74). There were 54.8% cases associated with stone disease. The most common histopatology was Transitional Cell Carcinoma (TCC) (47.6%). Ninety two point nine percent cases with Squamous Cell Carcinoma (SCC) are associated with stone or history of operation for stone removal. Symptom of flank tumor occurred in 61.0 % patients, flank pain 58.5 %, and hematuria 53.7 %. Only 71.4 % of cases were detected pre operatively. Pre operative imaging detection were 89.3%, 53.8%, 20.7% for CT Scan USG and IVU respectively . Fifty two point five percents of patients were found on Stage IV and 47.8 % of these patients were associated with stone disease. Most of patients with renal pelvis and ureter carcinoma were associated with stone disease, especially in patients with SCC tumors. There are still some problems in detecting these tumors especially in early stage.

Page 15 of 57 | Total Record : 562

13 14 15 16 17

Filter by Year

2007 2025

Filter By Issues

All Issue Vol 19, No 3 (2025): September Vol 19, No 2 (2025): June Vol 19, No 1 (2025): March Vol 18, No 4 (2024): December Vol 18, No 3 (2024): September Vol 18, No 2 (2024): June Vol 18, No 1 (2024): March Vol 17, No 4 (2023): December Vol 17, No 3 (2023): September Vol 17, No 2 (2023): June Vol 17, No 1 (2023): March Vol 16, No 4 (2022): December Vol 16, No 3 (2022): September Vol 16, No 2 (2022): June Vol 16, No 1 (2022): March Vol 15, No 4 (2021): December Vol 15, No 3 (2021): September Vol 15, No 2 (2021): June Vol 15, No 1 (2021): March Vol 14, No 4 (2020): December Vol 14, No 3 (2020): September Vol 14, No 2 (2020): June Vol 14, No 1 (2020): March Vol 13, No 4 (2019): December Vol 13, No 3 (2019): September Vol 13, No 2 (2019): June Vol 13, No 1 (2019): March Vol 12, No 4 (2018): October-December Vol 12, No 3 (2018): July-September Vol 12, No 2 (2018): April-June Vol 12, No 1 (2018): Jan - Mar Vol 11, No 4 (2017): October- December 2017 Vol 11, No 3 (2017): July - September 2017 Vol 11, No 2 (2017): April - June Vol 11, No 1 (2017): Jan-Mar Vol 10, No 4 (2016): October - December 2016 Vol 10, No 3 (2016): July - September 2016 Vol 10, No 2 (2016): April - June 2016 Vol 10, No 1 (2016): Jan - Mar 2016 Vol 9, No 4 (2015): Okt - Des 2015 Vol 9, No 3 (2015): Jul - Sept 2015 Vol 9, No 2 (2015): April-Juni 2015 Vol 9, No 1 (2015): Jan - Mar 2015 Vol 8, No 4 (2014): Oct - Dec 2014 Vol 8, No 3 (2014): Jul - Sep 2014 Vol 8, No 2 (2014): April-Juni 2014 Vol 8, No 1 (2014): Jan - Mar 2014 Vol 7, No 4 (2013): Oct - Dec 2013 Vol 7, No 3 (2013): Jul - Sep 2013 Vol 7, No 2 (2013): Apr - Jun 2013 Vol 7, No 1 (2013): Jan - Mar 2013 Vol 6, No 4 (2012): Oct - Dec 2012 Vol 6, No 3 (2012): Jul - Sep 2012 Vol 6, No 2 (2012): Apr - Jun 2012 Vol 6, No 1 (2012): Jan - Mar 2012 Vol 5, No 4 (2011): Oct - Dec 2011 Vol 5, No 3 (2011): Jul - Sep 2011 Vol 5, No 2 (2011): Apr - Jun 2011 Vol 5, No 1 (2011): Jan - Mar 2011 Vol 4, No 4 (2010): Oct - Dec 2010 Vol 4, No 3 (2010): Jul - Sep 2010 Vol 4, No 2 (2010): Apr - Jun 2010 Vol 4, No 1 (2010): Jan - Mar 2010 Vol 3, No 4 (2009): Oct - Dec 2009 Vol 3, No 3 (2009): Jul - Sep 2009 Vol 3, No 2 (2009): Apr - Jun 2009 Vol 3, No 1 (2009): Jan - Mar 2009 Vol 2, No 4 (2008): Oct - Dec 2008 Vol 2, No 3 (2008): Jul - Sep 2008 Vol 2, No 2 (2008): Apr - Jun 2008 Vol 2, No 1 (2008): Jan - Mar 2008 Vol 1, No 4 (2007): Oct - Dec 2007 Vol 1, No 3 (2007): Jul - Sep 2007 Vol 1, No 2 (2007): Apr - Jun 2007 Vol 1, No 1 (2007): Jan - Mar 2007 More Issue

Home Page

OAI Link

Editorial Team

Contact

Reviewer

Google Scholar

Contact Name
Bayu Brahma

Contact Email
journal.cancer@gmail.com

Phone
+628176389956

Journal Mail Official
admin@indonesianjournalofcancer.or.id

Editorial Address
National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta

Location
Kota adm. jakarta barat,

Dki jakarta

INDONESIA

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Home Page

OAI Link

Editorial Team

Contact

Reviewer

Google Scholar

Contact Name Bayu Brahma

Contact Email journal.cancer@gmail.com

Phone +628176389956

Journal Mail Official admin@indonesianjournalofcancer.or.id

Editorial Address National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta

Location Kota adm. jakarta barat, Dki jakarta INDONESIA

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Abstract

Contact Name
Bayu Brahma

Contact Email
journal.cancer@gmail.com

Phone
+628176389956

Journal Mail Official
admin@indonesianjournalofcancer.or.id

Editorial Address
National Cancer Center - Dharmais Cancer Hospital Research and Development Building, 3rd-floor Jl. Letjen S. Parman Kav. 84-86, Slipi West Jakarta

Location
Kota adm. jakarta barat,

Dki jakarta

INDONESIA